Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.

about

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.

Item

http://www.wikidata.org/entity/Q55002072

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Randomized, phase I/II study o ...... ced pancreatic adenocarcinoma.

@en

Randomized, phase I/II study o ...... ced pancreatic adenocarcinoma.

@nl

type

Item

label

Randomized, phase I/II study o ...... ced pancreatic adenocarcinoma.

@en

Randomized, phase I/II study o ...... ced pancreatic adenocarcinoma.

@nl

prefLabel

Randomized, phase I/II study o ...... ced pancreatic adenocarcinoma.

@en

Randomized, phase I/II study o ...... ced pancreatic adenocarcinoma.

@nl

P1476

Randomized, phase I/II study o ...... ced pancreatic adenocarcinoma.

@en

P2093

David R Fogelman

http://www.w3.org/2001/XMLSchema#string

Gauri R Varadhachary

http://www.w3.org/2001/XMLSchema#string

Michael J Overman

http://www.w3.org/2001/XMLSchema#string

Milind Javle

http://www.w3.org/2001/XMLSchema#string

Priya R Bhosale

http://www.w3.org/2001/XMLSchema#string

Rachna T Shroff

http://www.w3.org/2001/XMLSchema#string

Reham Abdel-Wahab

http://www.w3.org/2001/XMLSchema#string

Robert A Wolff

http://www.w3.org/2001/XMLSchema#string

Xuemei Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy.

KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer.

Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.

NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer.

Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.

P2888

s13045-018-0616-2

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13045-018-0616-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1104286218

http://www.w3.org/2001/XMLSchema#string

P698

29843755

http://www.w3.org/2001/XMLSchema#string

P921

adenocarcinoma

P932

5975422

http://www.w3.org/2001/XMLSchema#string